Integration of systems biology with organs-on-chips to humanize therapeutic development

Progress in Biomedical Optics and Imaging - Proceedings of SPIE

Volumn 10061, Issue , 2017, Pages

  Edington, Collin D ^a   Cirit, Murat ^a   Chen, Wen Li Kelly ^a   Clark, Amanda M ^a   Wells, Alan ^b   Trumper, David L ^a   Griffith, Linda G ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

3D liver culture; Drug development; Inflammation; Intestine; Organ crosstalk; Organs on chips; Perfusion; Tissue chip

Indexed keywords

BIOMEMS; CELL SIGNALING; COMPLEX NETWORKS; CROSSTALK; MICROFLUIDICS; MICROSYSTEMS; SIGNALING; STEM CELLS; TISSUE; TISSUE ENGINEERING;

DRUG DEVELOPMENT; INFLAMMATION; INTESTINE; LIVER CULTURE; ON CHIPS; PERFUSION;

PHYSIOLOGICAL MODELS;

EID: 85018876712     PISSN: 16057422     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.2256078     Document Type: Conference Paper

References (68)

1. Sung, J. H., Esch, M. B., Prot, J.-M., Long, C. J., et al., "Microfabricated mammalian organ systems and their integration into models of whole animals and humans," Lab on a Chip 13, 1201-1212 (2013).
2. Caplin, J. D., Granados, N. G., James, M. R., Montazami, R., et al., "Microfluidic Organ-on-a-Chip Technology for Advancement of Drug Development and Toxicology," Advanced Healthcare Materials 4, 1426-1450 (2015).
3. Cook, D., Brown, D., Alexander, R., March, R., et al., "Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework," Nat Rev Drug Discov 13, 419-31 (2014).
4. Anstee, Q., Targher, G. and Day, C., "Progression of NAFLD to diabetes mellitus, cardiovascular disease, or cirrhosis," Nat Rev Gastroenterol Hepatol 10, 330-344 (2013).
5. Brunt, E. M., Wong, V. W., Nobili, V., Day, C. P., et al., "Nonalcoholic fatty liver disease," Nat Rev Dis Primers 1, 15080 (2015).
6. Cassidy, S. and Syed, B. A., "Nonalcoholic steatohepatitis (NASH) drugs market," Nat Rev Drug Discov 15, 745-746 (2016).
7. DeFronzo, R., Tripathy, D., Schwenke, D., Banerji, M., et al., "Prevention of Diabetes With Pioglitazone in ACT NOW Physiologic Correlates," Diabetes 62, 3920-3926 (2013).
8. Stafford, J. and Elasy, T., "Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes," VascHealth Risk Management 3, 503-510 (2007).
9. Vercellini, P., Vigano, P., Somigliana, E. and Fedele, L., "Endometriosis: pathogenesis and treatment," Nature Publishing Group 10, 261-275 (2013).
10. Benagiano, G., Habiba, M., Brosens, I., Habiba, M., et al., "The pathophysiology of uterine adenomyosis: An update," Fertility and Sterility 98, 572-579 (2012).
11. Beste, M. T., Pfäffle-Doyle, N., Prentice, E. A., Morris, S. N., et al., "Molecular network analysis of endometriosis reveals a role for c-Jun-regulated macrophage activation.," Science Translational Medicine 6, 222ra16 (2014).
12. Koninckx, P. R., Craessaerts, M., Timmerman, D., Cornillie, F., et al., "Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial," Hum Reprod 23, 2017-23 (2008).
13. Hussein, M., Chai, D. C., Kyama, C. M., Mwenda, J. M., et al., "c-Jun NH2-terminal kinase inhibitor bentamapimod reduces induced endometriosis in baboons: an assessor-blind placebo-controlled randomized study," Fertil Steril 105, 815-24 e5 (2016).
14. D'Hooghe, T. M., Nugent, N. P., Cuneo, S., Chai, D. C., et al., "Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo-and drug-controlled study," Biol Reprod 74, 131-6 (2006).
15. Grund, E. M., Kagan, D., Tran, C. A., Zeitvogel, A., et al., "Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells," Mol Pharmacol 73, 1394-404 (2008).
16. Maher, J. J., "Modeling fatty liver disease in animals: Is there an optimal approach, and is the effort worthwhile," Hepatology 64, 1398-1400 (2016).
17. Lee, S., Zhang, C., Kilicarslan, M., Piening, B. D., et al., "Integrated Network Analysis Reveals an Association between Plasma Mannose Levels and Insulin Resistance," Cell Metab 24, 172-84 (2016).
18. Ip, B., Cilfone, N. A., Belkina, A. C., DeFuria, J., et al., "Th17 cytokines differentiate obesity from obesityassociated type 2 diabetes and promote TNFalpha production," Obesity (Silver Spring) 24, 102-12 (2016).
19. Miller, M. A., Meyer, A. S., Beste, M. T., Lasisi, Z., et al., "ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling.," Proceedings of the National Academy of Sciences 110, E2074-E2083 (2013).
20. Bruner-Tran, K., Ding, T. and Osteen, K., "Dioxin and Endometrial Progesterone Resistance," Semin Reprod Med 28, 059-068 (2010).
21. Lu, X. and Kang, Y., "Organotropism of breast cancer metastasis," J Mammary Gland Biol Neoplasia 12, 153-62 (2007).
22. Kalimutho, M., Parsons, K., Mittal, D., Lopez, J. A., et al., "Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease," Trends Pharmacol Sci 36, 822-46 (2015).
23. Miller, M. A., Oudin, M. J., Sullivan, R. J., Wang, S. J., et al., "Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance," Cancer Discov 6, 382-99 (2016).
24. Unger, C., Kramer, N., Walzl, A., Scherzer, M., et al., "Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development," Adv Drug Deliv Rev 79-80, 50-67 (2014).
25. Gilbert, P. and Weaver, V., "Cellular adaptation to biomechanical stress across length scales in tissue homeostasis and disease," Semin Cell Dev Biol. In Press, (2016).
26. Rothberg, J. M., Sameni, M., Moin, K. and Sloane, B. F., "Live-cell imaging of tumor proteolysis: impact of cellular and non-cellular microenvironment," Biochim Biophys Acta 1824, 123-32 (2012).
27. Sung, K. E. and Beebe, D. J., "Microfluidic 3D models of cancer," Adv Drug Deliv Rev 79-80, 68-78 (2014).
28. Stroock, A. D. and Fischbach, C., "Microfluidic culture models of tumor angiogenesis," Tissue Engineering Part A 16, 2143-2146 (2010).
29. Sobrino, A., Phan, D. T., Datta, R., Wang, X., et al., "3D microtumors in vitro supported by perfused vascular networks," Sci Rep 6, 31589 (2016).
30. Wang, X., Phan, D. T., Sobrino, A., George, S. C., et al., "Engineering anastomosis between living capillary networks and endothelial cell-lined microfluidic channels," Lab Chip 16, 282-90 (2016).
31. Roudsari, L. C. and West, J. L., "Studying the influence of angiogenesis in in vitro cancer model systems," Adv Drug Deliv Rev 97, 250-9 (2016).
32. Zervantonakis, I. K., Hughes-Alford, S. K., Charest, J. L., Condeelis, J. S., et al., "Three-dimensional microfluidic model for tumor cell intravasation and endothelial barrier function," Proc Natl Acad Sci U S A 109, 13515-20 (2012).
33. Jeon, J. S., Bersini, S., Gilardi, M., Dubini, G., et al., "Human 3D vascularized organotypic microfluidic assays to study breast cancer cell extravasation," Proc Natl Acad Sci U S A 112, 214-9 (2015).
34. Bianconi, E., Piovesan, A., Facchin, F., Beraudi, A., et al., "An estimation of the number of cells in the human body," Ann Hum Biol 40, 463-71 (2013).
35. Au, S. H., Storey, B. D., Moore, J. C., Tang, Q., et al., "Clusters of circulating tumor cells traverse capillary-sized vessels," Proc Natl Acad Sci U S A 113, 4947-52 (2016).
36. Clark, A. M., Ma, B., Taylor, D. L., Griffith, L., et al., "Liver metastases: Microenvironments and ex-vivo models," Exp Biol Med (Maywood) 241, 1639-52 (2016).
37. Chao, Y., Wu, Q., Acquafondata, M., Dhir, R., et al., "Partial Mesenchymal to Epithelial Reverting Transition in Breast and Prostate Cancer Metastases," Cancer Microenvironment 5, 19-28 (2011).
38. Chao, Y., Wu, Q., Shepard, C. and Wells, A., "Hepatocyte induced re-expression of E-cadherin in breast and prostate cancer cells increases chemoresistance," Clin Exp Metastasis 29, 39-50 (2011).
39. Chao, Y. L., Shepard, C. R. and Wells, A., "Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition," Mol Cancer 9, 179 (2010).
40. Powers, M. J., Domansky, K., Kaazempur-Mofrad, M. R., Kalezi, A., et al., "A microfabricated array bioreactor for perfused 3D liver culture," Biotechnol Bioeng 78, 257-69 (2002).
41. Domansky, K., Inman, W., Serdy, J., Dash, A., et al., "Perfused multiwell plate for 3D liver tissue engineering," Lab on a Chip 10, 51-58 (2010).
42. Ebrahimkhani, M. R., Nieman Shepard, J. A., Raredon, M. S. B., Hughes, D. J., et al., "Bioreactor Technologies to Support Liver Function In Vitro," Advanced Drug Delivery Reviews Apr, 132-57 (2014).
43. Sarkar, U., Rivera-Burgos, D., Large, E. M., Hughes, D. J., et al., "Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor," Drug Metab Dispos 43, 1091-9 (2015).
44. Dash, A., Inman, W., Hoffmaster, K., Sevidal, S., et al., "Liver tissue engineering in the evaluation of drug safety.," Expert Opin Drug Metab Toxicol 5, 1159-1174 (2009).
45. Regehr, K. J., Domenech, M., Koepsel, J. T., Carver, K. C., et al., "Biological implications of polydimethylsiloxanebased microfluidic cell culture," Lab on a Chip 9, 2132-2139 (2009).
46. Long, T., Cosgrove, P., Dunn, R. n., Stolz, D., et al., "Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three Dimensional Perfusable Human Liver Coculture Platform," Drug Metab Dispos 44, 1940-1948 (2016).
47. Yates, C., Shepard, C. R., Papworth, G., Dash, A., et al., "Novel three-dimensional organotypic liver bioreactor to directly visualize early events in metastatic progression.," Adv. Cancer Res. 97, 225-246 (2007).
48. Usta, O. B., McCarty, W. J., Bale, S., Hegde, M., et al., "Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution of in-vitro liver technologies," Technology (Singap World Sci) 3, 1-26 (2015).
49. Griffith, L. G., Wells, A. and Stolz, D. B., "Engineering liver," Hepatology 60, 1426-1434 (2014).
50. Tsamandouras, N., Kostrzewski, T., Stokes, C., Griffith, L., et al., "Quantitative assessment of population variability in hepatic drug metabolism using a perfused 3D human liver microphysiological system.," J Pharmacol Exp Ther. 360, 95-105 (2016).
51. Vivares, A., Salle-Lefort, S., Arabeyre-Fabre, C., Ngo, R., et al., "Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device," Xenobiotica 45, 29-44 (2015).
52. Sarkar, U., Rivera-Burgos, D., Large, E. M., Hughes, D. J., et al., "Metabolite Profiling and Pharmacokinetic Evaluation of Hydrocortisone in a Perfused Three-Dimensional Human Liver Bioreactor," Drug Metab Dispos 43, 1091-1099 (2015).
53. Kostrzewski, T., Cornforth, T., Snow, S., Ouro-Gnao, L., et al., "Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease," World J Gastroenterol Accepted for publication, (2016).
54. Wheeler, S. E., Clark, A. M., Taylor, D. P., Young, C. L., et al., "Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system," Br J Cancer 111, 2342-50 (2014).
55. Neiman, J. A. S., Raman, R., Chan, V., Rhoads, M. G., et al., "Photopatterning of Hydrogel Scaffolds Coupled to Filter Materials Using Stereolithography for Perfused 3D Culture of Hepatocytes," Biotechnology and Bioengineering 112, 777-787 (2015).
56. Clark, A., Wheeler, S., Young, C., Stockdale, L., et al., "A liver microphysiological system of tumor cell dormancy and inflammatory responsiveness is affected by scaffold properties," Lab Chip 17, 156-168 (2017).
57. Mahler, G. J., Esch, M. B., Tako, E., Southard, T. L., et al., "Oral exposure to polystyrene nanoparticles affects iron absorption," Nat Nanotechnol 7, 264-71 (2012).
58. Hall, R., Miller, R., Peatfield, A. and Richardson, P., "A colorimetric assay for mucous glycoproteins using Alcian Blue," Biochem Soc Trans. 8, 72 (1980).
59. Chen, W. L. K., Edington, C., Suter, E., Yu, J., et al., "Integrated Gut/Liver Microphysiological Systems Platform Elucidates Inflammatory Cytokine/Chemokine Inter-Tissue Crosstalk," Submitted, (2017).
60. Wagner, I., Materne, E.-M., Brincker, S., Süßbier, U., et al., "A dynamic multi-organ-chip for long-term cultivation and substance testing proven by 3D human liver and skin tissue co-culture," Lab Chip 13, 3538 (2013).
61. Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., et al., "A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents," Lab Chip 15, 2688-99 (2015).
62. Iori, E., Vinci, B., Murphy, E., Marescotti, M. C., et al., "Glucose and fatty acid metabolism in a 3 tissue in-vitro model challenged with normo-and hyperglycaemia," PLoS One 7, e34704 (2012).
63. Guzzardi, M. A., Domenici, C. and Ahluwalia, A., "Metabolic control through hepatocyte and adipose tissue crosstalk in a multicompartmental modular bioreactor," Tissue Eng Part A 17, 1635-42 (2011).
64. Knight-Schrijver, V. R., Chelliah, V., Cucurull-Sanchez, L. and Le Novere, N., "The promises of quantitative systems pharmacology modelling for drug development," Comput Struct Biotechnol J 14, 363-370 (2016).
65. Yang, R., Niepel, M., Mitchison, T. K. and Sorger, P. K., "Dissecting variability in responses to cancer chemotherapy through systems pharmacology," Clin Pharmacol Ther 88, 34-8 (2010).
66. Abaci, H. E. and Shuler, M. L., "Human-on-a-chip design strategies and principles for physiologically based pharmacokinetics/pharmacodynamics modeling," Integr Biol (Camb) 7, 383-91 (2015).
67. Stokes, C. L., Cirit, M. and Lauffenburger, D. A., "Physiome-on-a-Chip: The Challenge of 'Scaling' in Design, Operation, and Translation of Microphysiological Systems," CPT: Pharmacometrics & Systems Pharmacology 4, 559-562 (2015).
68. Yu, J., Cilfone, N. A., Large, E. M., Sarkar, U., et al., "Quantitative Systems Pharmacology Approaches Applied to Microphysiological Systems (MPS): Data Interpretation and Multi-MPS Integration," CPT Pharmacometrics Syst. Pharmacol. 4, 585-94 (2015).